Sanofi bags 300m from US investor Blackstone
Sanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.
Join 900 US CEOs protest against Ukraine invasion
US Life Science leaders pledge to economically disengage from Russia.
Join 900 US CEOs protest against Ukraine war
US Life Science leaders pledge to economically disengage from Russia.
Scenic Biotech BV announces $31m financing
Scenic Biotech BV will use an incoming $31m (28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease.
·
Kurma Partners closes growth fund at 160m
French venture capital expert Kurma Partners has closed its Growth Opportunities Fund at 160m and targets a final closing at 250m.
mRNA for Africa
Moderna will build its first mRNA production facility in Kenya, investing up to US$500m.
Epsilogen raise £30.75m in Series B financing
IgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer.
Syndesi swallowed by Abbvie
AbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.
Meletios Therapeutics licences antiviral patent
Paris-based Meletios Therapeutics SA has licenced know-how from the Institut Pasteur for the development of a new class of antivirals-
TargED Biopharmaceuticals BV raises 39m in Series A financing
TargED Biopharmaceuticals will use 39m from a Series A financing to bring its thrombolytic treatment to patients.